Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is an important cardiovascular disease with sudden cardiac death as the most devastating presentation. Implantable cardioverter defibrillators (ICD) are the optimal therapy for prevention of sudden death from ventricular tachycardia or fibrillation of any cause. While there is no controversy with implanting ICDs in patients who have already survived a cardiac arrest, identifying high-risk patients for primary prevention in this disease remains a challenge. Implanting ICDs in patients with HCM is an important clinical consideration since many individuals could achieve normal or near-normal lifespans with this protection.

[1]  G. Boriani,et al.  Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? , 2004, Circulation.

[2]  C. Semsarian,et al.  Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[3]  L. Fananapazir,et al.  Efficacy of Implantable Cardioverter Defibrillator Therapy for Primary and Secondary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy , 2003, Pacing and clinical electrophysiology : PACE.

[4]  F. Bracke The Lead Extractor's Toolbox: A Review Of Current Endovascular Pacemaker And ICD Lead Extraction Techniques , 2003, Indian pacing and electrophysiology journal.

[5]  Bracke Fa,et al.  Review Article The Lead Extractor's Toolbox: A Review Of Current Endovascular Pacemaker And ICD Lead Extraction Techniques , 2003 .

[6]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[7]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[8]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[9]  M. Josephson,et al.  Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). , 1999, Circulation.

[10]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. , 1999, JAMA.

[11]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[12]  Indian Pacing and Electrophysiology Journal , 2022 .